**Core Concept**
Sulfonylureas are a class of medications used to manage type 2 diabetes mellitus by stimulating insulin release from the pancreatic beta cells. In patients with chronic kidney disease (CKD), the choice of sulfonylurea is crucial due to the potential for renal excretion and accumulation of the medication.

**Why the Correct Answer is Right**
Glyburide (also known as glibenclamide) is a second-generation sulfonylurea that has a long half-life and is primarily metabolized by the liver. Its active metabolite is excreted by the kidneys, which may lead to accumulation in patients with CKD. In contrast, glipizide has a shorter half-life and is primarily excreted by the liver, making it a safer choice in CKD patients. Glipizide also has a lower risk of hypoglycemia due to its shorter duration of action.

**Why Each Wrong Option is Incorrect**
* **Option A:** Glyburide is not a good choice in CKD patients due to its potential for accumulation and increased risk of hypoglycemia.
* **Option B:** This option is not provided.
* **Option C:** This option is not provided.
* **Option D:** This option is not provided.

**Clinical Pearl / High-Yield Fact**
When prescribing sulfonylureas to patients with CKD, it is essential to consider the pharmacokinetics of the medication and choose a agent with a shorter half-life and minimal renal excretion.

**Correct Answer: C. Glipizide**